SCHEMBL2477504

SCHEMBL2477504

C#CCN(C)[C@H](COS(=O)(=O)c1ccc(C)cc1)Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.53
MAOA P21397 6/20 0.47
CYP1A2 P05177 3/20 0.47
TSHR P16473 2/20 0.47
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
ADRA1A P35348 1/20 0.47
SNCA P37840 1/20 0.47
OPRK1 P41145 1/20 0.47
CYP2D6 P10635 1/20 0.47
PKM P14618 1/20 0.47
MAPK1 P28482 1/20 0.46
KDM4E B2RXH2 1/20 0.46
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
STAT3 P40763 1/20 0.37
MCHR1 Q99705 1/20 0.37
GAA P10253 1/20 0.37
CNR2 P34972 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477505 1.00 MAOB (0.53) MAOBMAOACYP1A2TSHRADRA2A
SCHEMBL2477506 1.00 MAOB (0.53) MAOBMAOACYP1A2TSHRADRA2A
SCHEMBL2474561 0.90 MAOB (0.52) MAOBMAOACYP1A2TSHRADRA2A
SCHEMBL2474560 0.90 MAOB (0.52) MAOBMAOACYP1A2TSHRADRA2A
SCHEMBL2474070 0.83 MAOB (0.60) MAOBMAOACYP1A2TSHRADRA2A
SCHEMBL2474314 0.83 MAOB (0.60) MAOBMAOACYP1A2TSHRADRA2A
SCHEMBL2474342 0.83 MAOB (0.60) MAOBMAOACYP1A2TSHRADRA2A
SCHEMBL2474432 0.83 MAOB (0.57) MAOBTSHRPKMMAPK1KDM4E
SCHEMBL2474429 0.83 MAOB (0.57) MAOBTSHRPKMMAPK1KDM4E
SCHEMBL2474434 0.83 MAOB (0.57) MAOBTSHRPKMMAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266506-B2 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PIRAMAL IMAGING SA (CH) 2019-04-23 US disclosed
US-20180022719-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PIRAMAL IMAGING SA (CH) 2018-01-25 US disclosed
US-20180022719-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PIRAMAL IMAGING SA (CH) 2018-01-25 US disclosed
EP-2388245-B1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PIRAMAL IMAGING SA (CH) 2017-07-12 EP disclosed
EP-2388245-B1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PIRAMAL IMAGING SA (CH) 2017-07-12 EP disclosed
US-9682944-B2 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PIRAMAL IMAGING SA (CH) 2017-06-20 US disclosed
US-9682944-B2 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PIRAMAL IMAGING SA (CH) 2017-06-20 US disclosed
EP-2217549-B1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PIRAMAL IMAGING SA (CH) 2017-04-19 EP disclosed
US-20150030539-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PIRAMAL IMAGING SA (CH) 2015-01-29 US disclosed
US-20150030539-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PIRAMAL IMAGING SA (CH) 2015-01-29 US disclosed
EP-2388245-A1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors Bayer Pharma AG (DE) 2011-11-23 EP disclosed
EP-2374779-A1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors Bayer Pharma Aktiengesellschaft (DE) 2011-10-12 EP disclosed
EP-2374779-A1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors Bayer Pharma Aktiengesellschaft (DE) 2011-10-12 EP disclosed
US-20100233086-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2010-09-16 US disclosed
US-20100233086-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2010-09-16 US disclosed
EP-2217549-A2 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS Bayer Schering Pharma Aktiengesellschaft (DE) 2010-08-18 EP disclosed
US-20090191129-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS Lantheus Biosciences Ltd. (GB) 2009-07-30 US disclosed
US-20090191129-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS Lantheus Biosciences Ltd. (GB) 2009-07-30 US disclosed
WO-2009052970-A2 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-04-30 WO disclosed
WO-2009052970-A2 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022719-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PMP22, MEN1, VHL MAOB 206/4885MAOA 788/4885CYP1A2 4196/4885
US-10266506-B2 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PMP22, MEN1, VHL MAOB 206/4885MAOA 788/4885CYP1A2 4196/4885
US-20150030539-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PMP22, MEN1, VHL MAOB 206/4885MAOA 788/4885CYP1A2 4196/4885
US-20090191129-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PMP22, MEN1, VHL MAOB 206/4885MAOA 788/4885CYP1A2 4196/4885
US-20100233086-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PMP22, MEN1, VHL MAOB 206/4885MAOA 788/4885CYP1A2 4196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.